Tatva Chintan Pharma Chem
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Tatva Chintan Pharma Chem is poised for a new growth phase, driven by management's focus on R&D-led innovation and strategic capacity expansion. Recent commentary highlights a strong volume-led growth in core segments, particularly in structure directing agents and phase transfer catalysts, despite facing temporary supply chain challenges in the electrolyte business. Vista's financial outlook reflects a moderate revenue growth trajectory, supported by improving margins as the company transitions to continuous flow chemistry, enhancing productivity. The strategic emphasis on high-value applications in agrochemicals and electronics aligns with industry trends favoring specialty chemicals, which are projected to grow at a CAGR of 10.10%. However, persistent margin pressures from global oversupply and rising input costs remain watchpoints. Over the next 12-24 months, key opportunities include the successful rollout of Euro-7 emission norms and the commercialization of semiconductor products, while headwinds may arise from geopolitical tensions and competitive pricing pressures. Overall, Tatva's disciplined capital allocation and focus on operational resilience position it well for sustainable growth, with an expected upside of 54.18% and a 12-month target price of INR 2461
Why We Like This Stock
- Strong volume-led growth in core segments, particularly in structure directing agents and phase transfer catalysts
- Management's focus on R&D-led innovation and capacity expansion aligns with favorable industry trends in specialty chemicals
- Transition to continuous flow chemistry is expected to enhance productivity and improve margins
Things To Watch Out For
- Persistent margin pressures from global oversupply and rising input costs could impact profitability
- Temporary supply chain challenges in the electrolyte business may hinder short-term performance
- Geopolitical tensions and competitive pricing pressures from Chinese manufacturers pose risks to market share
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 394 | 383 | 506 | 578 | 668 |
| Profit Before Tax (Cr.) | 44 | 8 | 57 | 72 | 87 |
| PBT Margin | 11.2% | 2.1% | 11.3% | 12.5% | 13.1% |
| Net Profit (Cr.) | 36 | 6 | 45 | 57 | 69 |
| Earnings Per Share | 15.2 | 2.7 | 19.2 | 24.5 | 29.6 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| ICICI Securities | ▲ Buy | 1,955 | 20-Jul-2026 |
Company Overview
Show Company Profile
Tatva Chintan Pharma Chem Limited engages in the manufacture and sale of specialty chemicals in India, Germany, the United States of America, China, Singapore, and internationally. It offers structure directing agents (SDAs); phase transfer catalysts (PTCs); electrolyte salts for super capacitor batteries; pharmaceutical and agrochemical intermediates, and other specialty chemicals (PASC); and brominated flame retardants. The company serves automotive, consumer electronics, pharmaceutical, agrochemicals, paints and coatings, dyes, and personal care sectors. Tatva Chintan Pharma Chem Limited was incorporated in 1996 and is headquartered in Vadodara, India.